{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:21:36Z","timestamp":1789572096271,"version":"build-2803163510"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1378\/chest.12-1604","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T08:25:16Z","timestamp":1368087916000},"page":"1478-1479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor"],"prefix":"10.1016","volume":"143","author":[{"given":"Nicholas G.","family":"Wysham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Allada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1378\/chest.12-1604_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.12-1604_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nbt0611-467","article-title":"Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis","volume":"29","author":"Garber","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1378\/chest.12-1604_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1378\/chest.12-1604_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJMe1115119","article-title":"Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms","volume":"366","author":"Tefferi","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.12-1604_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/EC.00039-10","article-title":"Cryptococcal interactions with the host immune system","volume":"9","author":"Voelz","year":"2010","journal-title":"Eukaryot Cell"},{"issue":"4","key":"10.1378\/chest.12-1604_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213603499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213603499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:35:40Z","timestamp":1757918140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369213603499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0012369213603499"],"URL":"https:\/\/doi.org\/10.1378\/chest.12-1604","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.12-1604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}